Howard J M, Vinayek R, Maton P N, Wank S A, Gardner J D, Jensen R T
J Clin Gastroenterol. 1987;9 Suppl 2:23-5. doi: 10.1097/00004836-198707002-00007.
The ability of famotidine to control gastric acid hypersecretion in 32 patients with Zollinger-Ellison syndrome was compared to that of cimetidine or ranitidine. Equipotent doses of each drug were determined in nine patients and famotidine was nine times more potent than ranitidine and 32 times as potent as cimetidine. Famotidine had a 30% longer duration of action than either ranitidine or cimetidine. The 32 patients were treated with famotidine for a mean follow-up of 10.5 months. No hematologic, biochemical, or clinical toxicity occurred. Famotidine appears to be the histamine H2-receptor antagonist of choice in the treatment of Zollinger-Ellison syndrome.
将法莫替丁与西咪替丁或雷尼替丁相比，评估了其对32例卓艾综合征患者胃酸分泌过多的控制能力。在9例患者中确定了每种药物的等效剂量，法莫替丁的效力比雷尼替丁高9倍，比西咪替丁高32倍。法莫替丁的作用持续时间比雷尼替丁或西咪替丁长30%。32例患者接受法莫替丁治疗，平均随访10.5个月。未发生血液学、生化或临床毒性。法莫替丁似乎是治疗卓艾综合征的首选组胺H2受体拮抗剂。
